PX
PXMD.US PaxMedica, Inc. Common Stock
- Market cap
- USD 63.1K
- P/E
- -
- P/B
- 0.98x
- ROE
- -
- Dividend yield
- 18,922,156.76%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2024.
Is PXMD.US undervalued?
Graham numberThe Graham number of PaxMedica, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
PaxMedica, Inc. Common Stock fundamental analysis
No fundamental analysis for PaxMedica, Inc. Common Stock yet.
PaxMedica, Inc. Common Stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About PaxMedica, Inc. Common Stock
PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies for the treatment of disorders with intractable neurologic symptoms. Its lead product candidate is PAX-101 that is in Phase 3 clinical trials, an intravenous formulation of suramin for the treatment of autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, fragile X syndrome, human African trypanosomiasis (HA…
Full company profilePaxMedica, Inc. Common Stock financial statements
2024 annualized: Fiscal year 2024 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2024, the balance sheet is the latest quarter. Figures change when the annual report is published.
PaxMedica, Inc. Common Stock annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | - | -599K | -5.57M | -7.20M | -10.6M | -16.1M | -10.1M |
| EBITDA | - | -599K | -5.62M | -7.20M | -16.5M | -16.1M | - |
| Net Income | - | -599K | -8.49M | -13.0M | -14.8M | -18.3M | -10.1M |
| EPS | - | -1.02 | -14 | -19 | -29 | -11 | -0.93 |
| Balance Sheet | |||||||
| Total Assets | 9.32K | 24.9K | 1.12M | 649K | 2.20M | 5.68M | 820K |
| Total Liabilities | 6.60K | 123K | 5.75M | 10.8M | 2.10M | 2.30M | 2.75M |
| Shareholders' Equity | 2.72K | -98.3K | -4.63M | -10.1M | 109K | 3.39M | -1.93M |
| Cash & Short-term Investments | 9.32K | 24.9K | 1.12M | 444K | 1.90M | 4.71M | 445K |
| Total Debt | - | - | 612K | - | 174K | - | - |
| Cash Flow | |||||||
| Operating Cash Flow | -280K | -419K | -2.35M | -5.51M | -6.07M | -10.8M | -6.67M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | - | -419K | -2.35M | -5.51M | -6.07M | -10.8M | -6.67M |
| Ratios | |||||||
| ROE | - | - | - | - | -13,604.8% | -540.3% | - |
| ROA | - | -2,399.5% | -755.5% | -2,008.9% | -671.5% | -322.0% | -1,229.9% |
| Debt to Equity | - | - | - | - | 1.60x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
PaxMedica, Inc. Common Stock dividends
- Dividend yield
- 18,922,156.76%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2023 | USD 11.9B | 7,184 | - |
| 2022 | USD 35.0K | 0.07 | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:17 on Oct 31, 2023.
Who owns PaxMedica, Inc. Common Stock
- Insiders 0.00%
- Institutions 0.15%
- Public & others 99.85%
- Shares outstanding 126M
- Free float 10.8M
Top funds holding PXMD.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Northern Trust Extended Eq Market Idx | 187.00 | 0.00% | 0.00% | Mar 2024 |
| NT Ext Eq Mkt Indx Fd DC Lending Tier 5 | 8.00 | 0.00% | 0.00% | Mar 2024 |
Top institutions holding PXMD.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Souders Financial Advisors | 40.0K | 0.51% | 0.00% | Mar 2024 |
| Virtu Financial LLC | 37.3K | 0.48% | -33.89% | Mar 2024 |
| Susquehanna International Group, LLP | 26.1K | 0.34% | 0.00% | Mar 2024 |
| TWO SIGMA SECURITIES, LLC | 16.5K | 0.21% | +47.93% | Mar 2024 |
| Tower Research Capital LLC | 7.02K | 0.09% | +4.09% | Mar 2024 |
| Advisor Group Holdings, Inc. | 60.00 | 0.00% | +3.45% | Mar 2024 |
| Wells Fargo & Co | 30.00 | 0.00% | +1,400.00% | Mar 2024 |
| Hartland & Co | 2.00 | 0.00% | -99.91% | Mar 2024 |
| JPMorgan Chase & Co | 0.00 | 0.00% | -100.00% | Mar 2024 |
| UBS Group AG | 0.00 | 0.00% | -100.00% | Mar 2024 |
PaxMedica, Inc. Common Stock company profile
- Company name
- PaxMedica, Inc. Common Stock
- Ticker
- PXMD.US
- Exchange
- USA Stocks
- Listed since
- Aug 26, 2022
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 6
- Fiscal year end
- December
- Address
- 303 South Broadway, Tarrytown, NY, United States, 10591
- Phone
- 914 987 2876
- Website
- paxmedica.com
About PaxMedica, Inc. Common Stock
PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies for the treatment of disorders with intractable neurologic symptoms. Its lead product candidate is PAX-101 that is in Phase 3 clinical trials, an intravenous formulation of suramin for the treatment of autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, fragile X syndrome, human African trypanosomiasis (HAT), and fragile X-associated tremor/ataxia syndrome. The company is developing PAX-102, an intranasal formulation of suramin for neurologic indications, as well as other new chemical entities that are targeted and selective antagonists of purine receptor subtypes; and PAX-HAT-301 for the treatment of HAT. It has a research collaboration agreement with PolarMar Health for Phase II clinical trial in austism spectrum disorder for emodin, which retains the rights for PolarMar to develop and commercialize any non-prescription supplement form of the product, and for PaxMedica, Inc. to retain exclusive rights to develop and commercialize a highly purified form of emodin. The company was formerly known as Purinix Pharmaceuticals LLC and changed its name to PaxMedica, Inc. in April 2020. PaxMedica, Inc. was incorporated in 2018 and is based in Tarrytown, New York.
PaxMedica, Inc. Common Stock management
1- Mr. Howard J. WeismanChief Executive Officer · born 1959